Potential for interactions between caspofungin and nelfinavir or rifampin

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 11, 2004, Pages 4306-4314

  Stone, Julie A ^a   Migoya, Elizabeth M ^a   Hickey, Lisa ^a   Winchell, Gregory A ^a   Deutsch, Paul J ^a   Ghosh, Kalyan ^a   Freeman, Amanda ^a   Bi, Sheng ^a   Desai, Rajesh ^a   Dilzer, Stacy C ^c   Lasseter, Kenneth C ^c   Kraft, Walter K ^b   Greenberg, Howard ^b   Waldman, Scott A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Clinical Pharmacology Associates Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; NELFINAVIR; RIFAMPICIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG INHIBITION; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

ADULT; ALGORITHMS; ANTIBIOTICS, ANTITUBERCULAR; ANTIFUNGAL AGENTS; AREA UNDER CURVE; DRUG COMBINATIONS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; LINEAR MODELS; MALE; NELFINAVIR; PEPTIDES, CYCLIC; RIFAMPIN;

EID: 7244258914     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.11.4306-4314.2004     Document Type: Article

References (17)

1. Arathoon, E.G., E. Gotuzzo, L. M. Noriega, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. A randomized, double-blind, multicenter study of caspofungin versus amphotericin in the treatment of oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 46:451-457.
2. Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332.
3. o derivatives. J. Med. Chem. 37:222-225.
4. Bowman, J. C., P. Scott Hicks, M. B. Kurtz, H. Rosen, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:3001-3012.
5. Fattinger, K., V. Cattori, B. Hagenbuch, P. J. Meier, B. Stieger. 2000. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2. Hepatology 32: 82-86.
6. Fromm, M. F. 2000. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:69-74.
7. Greiner, B., M. Eichelbaum, P. Fritz, et al. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Investig. 104:147-153.
8. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
9. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect for the Caspofungin Invasive Candidiasis Study Group. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
10. Sable, C. A., B.-Y. T. Nguyen, J. A. Chodakewitz, and M. J. DiNubile. 2002. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl. Infect. Dis. 4:25-30.
11. Schwartz, M., W. Kline, and B. Matuszewski. 1997. Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection. Anal. Chem. Acta 352:299-307.
12. Stone, J. A., S. D. Holland, P. J. Wickersham, A. Sterrett, M. Schwartz, C. Bonfiglio, M. Hesney, G. A. Winchell, P. J. Deutsch, H. Greenberg, T. L. Hunt, and S. A. Waldman. 2002. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. 46:739-745.
13. Stone, J. A., X. Xu, G. A. Winchell, P. J. Deutsch, P. G. Pearson, E. M. Migoya, G. C. Mistry, L. Xi, A. Miller, P. Sandhu, R. Singh, F. deLuna, S. C. Dilzer, and K. C. Lasseter. 2004. Disposition of caspofungin: role of distribution in determining plasma pharmacokinetics. Antimicrob. Agents Chemother. 48:815-823.
14. Van Montfoort J. E., B. Stieger, D. K. F. Meijer, H.-J. Weinmann, P. J. Meier, and K. E. Fattinger. 1999. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J. Pharmacol. Exp. Ther. 290:153-157.
15. Vazquez, J. A., M. Lynch, D. Boikov, and J. D. Sobel. 1997. In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1612-1614.
16. Villanueva, A., E. G. Arathoon, E. Gotuzzo, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2001. A randomized double-blind study of caspofungin versus amphotericin for the treatment of Candida esophagitis. Clin. Infect. Dis. 33:1529-1535.
17. Villanueva, A., E. Gotuzzo, E. Arathoon, L. M. Noriega, N. Kartsonis, R. Lupinacci, J. Smietana, R. S. Berman, M. J. DiNubile, and C. A. Sable. 2002. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113:294-299.